多肽类药物以其活性显著、特异性强、毒性较弱，在体内不易产生蓄积等独特优势而广为称道,但是抵御心肌肥厚的多肽类药物亟待开发。我们心脏发育研究团队于2003年克隆了一个在心脏特异性强表达的人类基因-叫做Lrrc10，可以通过抑制SRF转录活性的机制对于心肌肥厚具有明显的抵抗作用。更重要的是，其蛋白含有7个仅20个氨基酸大小的LRR结构域，单个的LRR结构域，就能和SRF发挥相互作用，并表现为较强的SRF转录活性的抑制,表现出一个诱人的多肽药物开发前景。本研究，申请人拟将Lrrc10的7个LRR进行分段克隆，以及寻找抵御心肌肥厚的最优化LRR片段，并人工合成小分子多肽，评价其在心脏保护中的功能。从而为开发特异性多肽药物提供实验依据。

Peptide drugs with its activity significantly, specificity, less toxicity, accumulate in body are most concerned, However, peptide drugs inhibiting cardiac hypertrophy need to be developed. We cloned a cardiac-specific expressing gene named Lrrc10 in 2003, which has a significant resistance to cardiac hypertrophy, throuh inhibition of SRF transcription activity. More importantly, the protein contains seven LRR domains of only 20 amino acids in size, and the single LRR domain interacts with SRF and exhibits a strong inhibition of SRF transcription activity, showing a promosing peptide drug development prospects. In this study, the applicant will split Lrrc10 7 LRRs and to find the optimal LRR fragment against cardiac hypertrophy and to synthesize small molecule polypeptides to evaluate their function in cardioprotection. This will provide an experimental basis for the development of specific peptide drugs.